10:28 EST Hims & Hers up 4.7% on report of drugmakers near deal for obesity drug prices
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target lowered to $59 from $66 at Seaport Research
- Sell Rating Issued for Hims & Hers Health Amid Sluggish Subscriber Growth and Margin Pressures
- Hims & Hers price target raised to $32 from $28 at BofA
- Strong Buy Rating for Hims & Hers Health: Impressive Growth and Strategic Expansion Drive Future Potential
- Cautious Outlook Amid Strategic Expansion: Hold Rating for Hims & Hers Health